Exacerbation of inflammatory bowel disease (IBD).
Avoid combining sulfasalazine with traditional NSAIDs.
Source: G&G 14e · p1112
NSAID · Cold and Flu Medication, Symptomatic Relief of Common Cold
Also known as Crocin Cold & Flu, Dolo Cold, Sumo Cold, FluCip, Sinarest, Vicks Action 500 Advance
Paracetamol exerts its analgesic and antipyretic effects primarily by inhibiting prostaglandin synthesis in the central nervous system. Caffeine acts as a central nervous system stimulant, enhancing the analgesic effect of paracetamol and counteracting the potential for sedation. Phenylephrine, an alpha-1 adrenergic agonist, causes vasoconstriction in the nasal mucosa, thereby reducing swelling and congestion. Combination rationale: This FDC combines a non-opioid analgesic and antipyretic (Paracetamol) with a central nervous system stimulant (Caffeine) to enhance the analgesic effect and counteract potential sedation, and a decongestant (Phenylephrine) to relieve nasal congestion. This combination provides comprehensive symptomatic relief for multiple common cold and flu symptoms such as fever, pain, and stuffy nose, improving patient convenience and compliance.
Category C (Phenylephrine is Category C; Paracetamol is Category B; Caffeine is Category B or C depending on dose and source). Overall, the combination is generally considered Category C due to Phenylephrine. Use only if the potential benefit justifies the potential risk to the fetus.
Paracetamol is generally considered safe during lactation. Caffeine is excreted into breast milk and can cause irritability or sleep disturbances in breastfed infants; use with caution. Phenylephrine can pass into breast milk and may potentially reduce milk supply, especially with prolonged use. It should be used with caution during breastfeeding, and infant monitoring for irritability or sleep issues is advised. Avoid prolonged or high-dose use.
Exacerbation of inflammatory bowel disease (IBD).
Avoid combining sulfasalazine with traditional NSAIDs.
Source: G&G 14e · p1112
Increased risk of nephrotoxicity.
Avoid concurrent use.
Source: KDT 7e · p746
Increased aminoglycoside levels and potential toxicity.
Monitor aminoglycoside levels and renal function; adjust dosage as needed.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider alternative analgesics or gastroprotective agents.
Source: KDT 7e
Enhanced CNS toxicity, seizures reported.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased bleeding risk.
Exercise extra caution and monitor for signs of bleeding.
Source: G&G 14e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents.
Source: KDT 7e
Increased nephrotoxicity.
Avoid concomitant use or monitor renal function closely.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Reduced effectiveness of ACE inhibitors. Marked hyperkalemia, potentially leading to cardiac arrhythmia.
Use with caution, especially in the elderly and in patients with hypertension, diabetes mellitus, or ischemic heart disease.
Source: G&G 14e · p836
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Continue into a citation-backed clinical answer with the drug context already attached.